Sysmex (OTCMKTS:SSMXY) Announces Quarterly Earnings Results

Sysmex (OTCMKTS:SSMXY) announced its earnings results on Thursday. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02), Zacks reports. The company had revenue of $877.92 million for the quarter, compared to analyst estimates of $862.45 million. Sysmex had a return on equity of 7.28% and a net margin of 7.13%. Sysmex updated its FY 2026 guidance to 0.370-0.370 EPS.

Sysmex Stock Up 3.2%

Shares of OTCMKTS SSMXY traded up $0.26 during midday trading on Friday, reaching $8.38. The company’s stock had a trading volume of 162,299 shares, compared to its average volume of 231,070. The company has a current ratio of 3.33, a quick ratio of 2.44 and a debt-to-equity ratio of 0.12. Sysmex has a fifty-two week low of $8.12 and a fifty-two week high of $18.10. The stock has a market capitalization of $5.28 billion, a price-to-earnings ratio of 22.05 and a beta of 1.10. The stock has a 50 day simple moving average of $8.72 and a 200-day simple moving average of $9.39.

Analyst Ratings Changes

Separately, Citigroup downgraded shares of Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold”.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.